These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36777381)

  • 1. Cost-effectiveness of stereotactic body radiotherapy versus conventional radiotherapy for the treatment of surgically ineligible stage I non-small cell lung cancer in the Brazilian public health system.
    Arruda GV; Lourenção M; de Oliveira JHC; Galendi JSC; Jacinto AA
    Lancet Reg Health Am; 2022 Oct; 14():100329. PubMed ID: 36777381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of hypofractionated versus conventional fractionated radiotherapy for the treatment of men with early glottic cancer: a study in the Brazilian public and private health system.
    Lourenção M; Arruda GV; Rocha LP; Galendi JSC; de Oliveira JC; Jacinto AA
    BMC Health Serv Res; 2023 Jun; 23(1):592. PubMed ID: 37291564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of stereotactic body radiotherapy versus conventional fractionated radiotherapy for medically inoperable, early-stage non-small cell lung cancer.
    Sun H; Wang H; Wei Y; Wang H; Jin C; Chen Y
    Cost Eff Resour Alloc; 2023 Jul; 21(1):46. PubMed ID: 37507748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis comparing conventional versus stereotactic body radiotherapy for surgically ineligible stage I non-small-cell lung cancer.
    Mitera G; Swaminath A; Rudoler D; Seereeram C; Giuliani M; Leighl N; Gutierrez E; Dobrow MJ; Coyte PC; Yung T; Bezjak A; Hope AJ
    J Oncol Pract; 2014 May; 10(3):e130-6. PubMed ID: 24643574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.
    Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer.
    Paix A; Noel G; Falcoz PE; Levy P
    Radiother Oncol; 2018 Sep; 128(3):534-540. PubMed ID: 29706462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC).
    Donovan EK; Xie F; Louie AV; Chu W; Siva S; Kapoor A; Swaminath A
    Clin Genitourin Cancer; 2022 Oct; 20(5):e353-e361. PubMed ID: 35490099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer.
    Sher DJ; Wee JO; Punglia RS
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e767-74. PubMed ID: 21300476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study.
    Wolff HB; Alberts L; van der Linden N; Bongers ML; Verstegen NE; Lagerwaard FJ; Hofman FN; Uyl-de Groot CA; Senan S; El Sharouni SY; Kastelijn EA; Schramel FMNH; Coupé VMH
    Lung Cancer; 2020 Mar; 141():89-96. PubMed ID: 31982640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of postmastectomy hypofractionated radiation therapy vs conventional fractionated radiation therapy for high-risk breast cancer.
    Yang J; Qi SN; Fang H; Song YW; Jin J; Liu YP; Wang WH; Yang Y; Tang Y; Ren H; Chen B; Lu NN; Tang Y; Li N; Jing H; Wang SL; Li YX
    Breast; 2021 Aug; 58():72-79. PubMed ID: 33933925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status.
    Kim H; Vargo JA; Ling DC; Beriwal S; Smith KJ
    Am J Clin Oncol; 2019 Nov; 42(11):837-844. PubMed ID: 31644441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck.
    Leung HW; Lang HC; Wang SY; Leung JH; Chan AL
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):489-495. PubMed ID: 33729079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Compared With Radiofrequency Ablation for Inoperable Colorectal Liver Metastases.
    Kim H; Gill B; Beriwal S; Huq MS; Roberts MS; Smith KJ
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1175-83. PubMed ID: 27130789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
    Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
    Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer.
    Simoes Correa-Galendi J; Del Pilar Estevez Diz M; Stock S; Müller D
    Appl Health Econ Health Policy; 2021 Jan; 19(1):97-109. PubMed ID: 32537695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microwave Ablation versus Stereotactic Body Radiotherapy for Stage I Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis.
    Wu X; Uhlig J; Blasberg JD; Gettinger SN; Suh RD; Solomon SB; Kim HS
    J Vasc Interv Radiol; 2022 Aug; 33(8):964-971.e2. PubMed ID: 35490932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer.
    Murphy JD; Chang DT; Abelson J; Daly ME; Yeung HN; Nelson LM; Koong AC
    Cancer; 2012 Feb; 118(4):1119-29. PubMed ID: 21773972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.
    Shah A; Hahn SM; Stetson RL; Friedberg JS; Pechet TT; Sher DJ
    Cancer; 2013 Sep; 119(17):3123-32. PubMed ID: 23720093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic Body Radiotherapy versus Low Dose Rate Brachytherapy for Localised Prostate Cancer: a Cost-Utility Analysis.
    Helou J; Torres S; Musunuru HB; Raphael J; Cheung P; Vesprini D; Chung HT; D'Alimonte L; Krahn M; Morton G; Loblaw A
    Clin Oncol (R Coll Radiol); 2017 Nov; 29(11):718-731. PubMed ID: 28916284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung Cancer.
    Kareff SA; Han S; Haaland B; Jani CJ; Kohli R; Aguiar PN; Huang Y; Soo RA; Rodríguez-Perez Á; García-Foncillas J; Dómine M; de Lima Lopes G
    JAMA Netw Open; 2024 May; 7(5):e2413938. PubMed ID: 38814640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.